CRISM Therapeutics Corporation (CRTX) - Net Assets
Based on the latest financial reports, CRISM Therapeutics Corporation (CRTX) has net assets worth GBX1.42 Million GBX (≈ $172.29 USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX1.80 Million ≈ $218.64 USD) and total liabilities (GBX381.00K ≈ $46.36 USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See CRTX equity to assets ratio to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX1.42 Million |
| % of Total Assets | 78.8% |
| Annual Growth Rate | -9.45% |
| 5-Year Change | -95.3% |
| 10-Year Change | -94.46% |
| Growth Volatility | 40.46 |
CRISM Therapeutics Corporation - Net Assets Trend (2006–2025)
This chart illustrates how CRISM Therapeutics Corporation's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see CRTX market cap overview.
Annual Net Assets for CRISM Therapeutics Corporation (2006–2025)
The table below shows the annual net assets of CRISM Therapeutics Corporation from 2006 to 2025. Also explore CRTX year-over-year net asset growth to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | GBX1.42 Million ≈ $172.29 |
-4.00% |
| 2024-12-31 | GBX1.48 Million ≈ $179.46 |
+294.16% |
| 2023-12-31 | GBX-759.66K ≈ $-92.43 |
-103.28% |
| 2022-12-31 | GBX23.13 Million ≈ $2.81K |
-23.19% |
| 2021-12-31 | GBX30.11 Million ≈ $3.66K |
-3.95% |
| 2020-12-31 | GBX31.35 Million ≈ $3.81K |
+53.04% |
| 2019-12-31 | GBX20.48 Million ≈ $2.49K |
-12.74% |
| 2018-12-31 | GBX23.48 Million ≈ $2.86K |
-16.75% |
| 2017-12-31 | GBX28.20 Million ≈ $3.43K |
+10.37% |
| 2016-12-31 | GBX25.55 Million ≈ $3.11K |
+68.03% |
| 2015-12-31 | GBX15.21 Million ≈ $1.85K |
-26.61% |
| 2014-12-31 | GBX20.72 Million ≈ $2.52K |
+14.76% |
| 2013-12-31 | GBX18.05 Million ≈ $2.20K |
+12.01% |
| 2012-12-31 | GBX16.12 Million ≈ $1.96K |
-23.93% |
| 2011-12-31 | GBX21.19 Million ≈ $2.58K |
-0.48% |
| 2010-12-31 | GBX21.29 Million ≈ $2.59K |
+28.87% |
| 2009-12-31 | GBX16.52 Million ≈ $2.01K |
+53.22% |
| 2008-12-31 | GBX10.78 Million ≈ $1.31K |
+65.01% |
| 2007-12-31 | GBX6.53 Million ≈ $795.02 |
-29.98% |
| 2006-12-31 | GBX9.33 Million ≈ $1.14K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to CRISM Therapeutics Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5412511090.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | GBX68.07 Million | 4807.06% |
| Other Comprehensive Income | GBX-8.77 Million | -619.07% |
| Other Components | GBX3.36 Million | 237.29% |
| Total Equity | GBX1.42 Million | 100.00% |
CRISM Therapeutics Corporation Competitors by Market Cap
The table below lists competitors of CRISM Therapeutics Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PowerHouse Energy Group Plc
LSE:PHE
|
$108.81K |
|
Tern Plc
LSE:TERN
|
$109.15K |
|
BSR Real Estate Investment Trust
TO:HOM-UN
|
$110.68K |
|
Bay Capital PLC
LSE:BAY
|
$110.72K |
|
Hydrogenone Capital Growth PLC
LSE:HGEN
|
$108.15K |
|
Cloudbreak Discovery PLC
LSE:CDL
|
$108.11K |
|
NB Distressed Debt New Glb
LSE:NBDG
|
$107.95K |
|
Catalyst Media Group PLC
LSE:CMX
|
$107.83K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CRISM Therapeutics Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,475,000 to 1,416,000, a change of -59,000 (-4.0%).
- Net loss of 1,903,000 reduced equity.
- New share issuances of 1,934,000 increased equity.
- Other comprehensive income increased equity by 561,000.
- Other factors decreased equity by 651,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX-1.90 Million | -134.39% |
| Share Issuances | GBX1.93 Million | +136.58% |
| Other Comprehensive Income | GBX561.00K | +39.62% |
| Other Changes | GBX-651.00K | -45.97% |
| Total Change | GBX- | -4.00% |
Book Value vs Market Value Analysis
This analysis compares CRISM Therapeutics Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 289.73x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.61x to 289.73x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | GBX18.48 | GBX11.25 | x |
| 2007-12-31 | GBX10.79 | GBX11.25 | x |
| 2008-12-31 | GBX14.85 | GBX11.25 | x |
| 2009-12-31 | GBX18.13 | GBX11.25 | x |
| 2010-12-31 | GBX17.80 | GBX11.25 | x |
| 2011-12-31 | GBX8.03 | GBX11.25 | x |
| 2012-12-31 | GBX7.47 | GBX11.25 | x |
| 2013-12-31 | GBX7.46 | GBX11.25 | x |
| 2014-12-31 | GBX7.69 | GBX11.25 | x |
| 2015-12-31 | GBX5.57 | GBX11.25 | x |
| 2016-12-31 | GBX7.52 | GBX11.25 | x |
| 2017-12-31 | GBX7.40 | GBX11.25 | x |
| 2018-12-31 | GBX5.76 | GBX11.25 | x |
| 2019-12-31 | GBX4.45 | GBX11.25 | x |
| 2020-12-31 | GBX4.68 | GBX11.25 | x |
| 2021-12-31 | GBX3.49 | GBX11.25 | x |
| 2022-12-31 | GBX2.66 | GBX11.25 | x |
| 2023-12-31 | GBX0.47 | GBX11.25 | x |
| 2024-12-31 | GBX0.24 | GBX11.25 | x |
| 2025-12-31 | GBX0.04 | GBX11.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CRISM Therapeutics Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -134.39%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -823.81%
- • Asset Turnover: 0.13x
- • Equity Multiplier: 1.27x
- Recent ROE (-134.39%) is below the historical average (-20.60%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | -17.19% | 0.00% | 0.00x | 1.00x | GBX-2.54 Million |
| 2007 | -30.16% | 0.00% | 0.00x | 1.03x | GBX-2.62 Million |
| 2008 | -20.71% | 0.00% | 0.00x | 1.03x | GBX-3.31 Million |
| 2009 | -10.98% | 0.00% | 0.00x | 1.02x | GBX-3.47 Million |
| 2010 | 1.70% | 0.00% | 0.00x | 0.99x | GBX-1.79 Million |
| 2011 | -32.67% | 0.00% | 0.00x | 1.56x | GBX-5.82 Million |
| 2012 | -25.14% | 0.00% | 0.00x | 1.00x | GBX-5.66 Million |
| 2013 | -20.82% | 0.00% | 0.00x | 1.00x | GBX-5.56 Million |
| 2014 | -6.57% | 0.00% | 0.00x | 1.02x | GBX-3.43 Million |
| 2015 | -4.50% | 0.00% | 0.00x | 1.05x | GBX-2.20 Million |
| 2016 | -20.39% | 0.00% | 0.00x | 1.14x | GBX-7.82 Million |
| 2017 | -4.24% | 0.00% | 0.00x | 1.03x | GBX-4.04 Million |
| 2018 | -13.31% | 0.00% | 0.00x | 1.11x | GBX-5.50 Million |
| 2019 | -8.91% | 0.00% | 0.00x | 1.04x | GBX-3.87 Million |
| 2020 | -9.03% | 0.00% | 0.00x | 1.03x | GBX-5.97 Million |
| 2021 | -5.12% | 0.00% | 0.00x | 1.04x | GBX-4.55 Million |
| 2022 | -10.58% | 0.00% | 0.00x | 1.03x | GBX-4.76 Million |
| 2023 | -6.01% | -435.56% | 0.35x | 0.04x | GBX-660.14K |
| 2024 | -32.88% | -2428.03% | 0.01x | 1.23x | GBX-632.55K |
| 2025 | -134.39% | -823.81% | 0.13x | 1.27x | GBX-2.04 Million |
Industry Comparison
This section compares CRISM Therapeutics Corporation's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $4,741,241
- Average return on equity (ROE) among peers: -88.44%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CRISM Therapeutics Corporation (CRTX) | GBX1.42 Million | -17.19% | 0.27x | $108.39K |
| 4BASEBIO UK SOCIETAS (4BB) | $7.12 Million | -72.33% | 0.64x | $904.35K |
| Aptamer Group PLC (APTA) | $899.87K | -50.56% | 0.55x | $111.57K |
| Arecor Therapeutics PLC (AREC) | $18.55 Million | -33.26% | 0.13x | $372.10K |
| Avacta Group PLC (AVCT) | $9.28 Million | -569.35% | 4.20x | $4.26 Million |
| BSF Enterprise Plc (BSFA) | $3.19 Million | -52.42% | 0.10x | $15.62K |
| Bioventix (BVXP) | $10.14 Million | 48.52% | 0.02x | $953.57K |
| Cizzle Biotechnology Holdings PLC (CIZ) | $4.79 Million | -16.27% | 0.70x | $72.34K |
| Fusion Antibodies PLC (FAB) | $169.29K | -50.27% | 1.19x | $148.66K |
| Faron Pharmaceuticals Oy (FARN) | $-11.48 Million | 0.00% | 0.00x | $485.05K |
About CRISM Therapeutics Corporation
CRISM Therapeutics Corporation develops a drug delivery technology for the clinical performance of cancer treatments for solid tumors through the local delivery of chemotherapy drugs in the British Virgin Islands. The company's lead product is ChemoSeed, which can be implanted directly into the tumour or the resection margin following the removal of a tumour. It also provides formulation and cons… Read more